Ergocalciferol (Vitamin D2)

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Finland: Devitol, Jekovit; France: Sterogyl, Uvesterol D; Greece: Ostelin, Sterogyl, Vitaminol; Hungary: Neogranormon; Italy: Ostelin, Vit. D2; Luxembourg: Sterogyl; Slovakia: Calciferol, Infadin, Vitamin D; UK: Ergocalciferol.

North America

Canada: Drisdol; USA: Drisdol, Vitamin D.

Latin America

Argentina: Ostelin, Raquiferol, Tanvimil D.

Drug combinations

Ergocalciferol: Ascorbic Acid (Vitamin C); Benzalkonium; Benzocaine; Biotin (Vitamin B~7~); Boric Acid; Calcium; Cobalt; Cobamamide; Cod Liver Oil; Cyanocobalamin (Vitamin B~12~); Cyproheptadine; Ferrous Fumarate; Ferrous Sulfate; Fish Liver; Fluoride; Folic Acid (Vitamin B~9~); Ginseng; Iron; Lanolin; Magnesium; Manganese; Molybdenum; Neomycin; Niacin (Vitamin B~3~); Niacinamide; Pantothenic Acid (Vitamin B~5~); Phosphorus; Phytomenadione (Vitamin K~1~); Pollen; Potassium; Pyridoxine (Vitamin B~6~); Retinol (Vitamin A); Riboflavin (Vitamin B~2~); Rutoside; Saccharomyces cerevisiae; Talc; Thiamine (Vitamin B~1~); Tocopherol (Vitamin E); Zinc


Ergocalciferol: C~28~H~44~O. Mw: 396.65. 9,10-Secoergosta-5, 7,10(19), 22-tetraen-3-ol, (3β,5Z,7E,22E). CAS-50-14-6.

Pharmacologic Category

Vitamins; Vitamin D. (ATC-Code: A11CC01).

Mechanism of action

Ergocalciferol increases intestinal absorption of calcium and phosphate and elevates serum calcium and phosphate concentrations sufficiently to permit bone mineralization. Also promotes calcium reabsorption by the kidneys. Activated form of ergocalciferol may have a negative feedback effect on PTH production.

Therapeutic use

Treatment of refractory rickets, hypophosphatemia, hypoparathyroidism. Dietary supplement.

Pregnancy and lactiation implications

Abnormalities observed in animal studies with maternal doses causing hypervitaminosis D. Caution if used in nursing women. Do not administer large doses of vitamin D analogs.

Unlabeled use

Prevention and treatment of vitamin D deficiency in chronic kidney disease.


Hypersensitivity to ergocalciferol or any component of the formulation. Hypercalcemia. Malabsorption syndrome. Hypervitaminosis D or abnormal sensitivity to toxic effects of vitamin D.

Warnings and precautions

Caution in cardiovascular disease, renal impairment, renal stones, arteriosclerosis, or diseases which impair vitamin D metabolism. Hypercalcemia might occur due to hypervitaminosis D. Acute hypercalcemia may increase risk of cardiac arrhythmias and seizures, and result in cardiac arrhythmias in presence of cardiac glycosides. Calcium supplementation is required. Range between therapeutic and toxic doses is narrow in vitamin D-resistant rickets. Effects of vitamin D can last ≥2 months after therapy is discontinued. May contain tartrazine (allergic reactions).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart